Pharma Lies, People Die: Myth-Busting Fact Sheet on Medicine Development and Pricing
TAGline • 2018By Bryn Gay, HCV Project Director, TAG and Claudine Guerra, CUNY DOWNLOAD to print this article as a poster (A1 size) The current leaders of the United States manufacture crises, media optics, and catchy sound bites to side step actual responsibility for tackling immensely complex policy issues like extortionately high prescription drug prices. The American…
The HCV Diagnostics Pipeline
Pipeline • 2018July 2018 by Bryn Gay Simpler Rapid, Point-of-Care Hepatitis C Diagnostics: Are We There Yet?1 To increase treatment rates and make a dent in the epidemic by 2030, countries need to scale up access to affordable, simple, rapid diagnostics, ensuring services reach people most at risk of HCV infection, including people who inject or use…
The Tuberculosis Treatment Pipeline for Children
Pipeline • 2018July 2018 by Lindsay McKenna Pharmacokinetic (PK) and safety studies in children continue to progress, producing a steady flow of data (Table 2). Yet the translation of research and development gains into policy and access for children with tuberculosis (TB) remains painfully slow. Additionally, target drug exposures are evolving. Studies underway or recently completed in…
Beyond Declarations: Lessons from the UN High-Level Meeting on TB on Building and Transforming Political Will into Real Access to Medicines
TAGline • 2018By Khairunisa Suleiman, Technical Co-Lead, Global TB CAB and Suraj Madoori, U.S. and Global Health Policy Director, TAG On Sept. 26, 2018, the world came together at the United Nations General Assembly in New York for the first-ever High-Level Meeting on Tuberculosis (TB HLM), bringing hope for new political will and resources to jump-start the…
Comment in Response to Proposed Rulemaking: Inadmissibility on Public Charge Grounds
Letters • 2018On October 10, 2018, the Trump Administration proposed sweeping regulations that would put the health and wellbeing of millions of families at risk. TAG is strongly opposed to these proposed changes; read the comment we submitted on December 7.
2018 Report on TB Research Funding Trends
TB R&D • 2018Global funding for tuberculosis (TB) research climbed to a previously unreported high of USD $772 million in 2017. This marks the second year in a row that funding for TB research and development (R&D) exceeded $700 million.
The HCV Treatment Pipeline
Pipeline • 2018July 2018 Annette Gaudino HCV TREATMENT PIPELINE: THE DEFERRED DREAM OF TREATMENT FOR ALL Generic combinations of direct-acting antivirals (DAAs), including sofosbuvir/daclatasvir show bioequivalence compared to originators with equivalent sustained virological responses (SVR). Both sofosbuvir/daclatasvir and sofosbuvir/ravidasvir demonstrate SVR rates of 97% at 12 weeks of treatment across genotypes, with further studies underway for genotypes…
The HIV Vaccines, Passive Immunization, and Antibody Gene Transfer Pipeline
Pipeline • 2018July 2018 by Richard Jefferys The most important news in preventive HIV vaccine research over the past year is the opening of a Phase IIb trial testing the efficacy of a prime-boost approach developed by Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson. The trial, known as Imbokodo…
The Tuberculosis Diagnosis Pipeline for Children
Pipeline • 2018July 2018 by Lindsay McKenna Existing tests and those under development that are designed to detect tuberculosis (TB) bacteria (see the Tuberculosis Diagnosis Pipeline, coming soon) are suboptimal for children, who often have fewer TB bacteria in their bodies than adults (paucibacillary disease). The usefulness of sputum-based tests is limited in young children, who often…
It’s up to You, New York: Moving towards HCV Elimination in the Empire State
TAGline • 2018By Annette Gaudino Governor Andrew Cuomo’s March 16 announcement committing New York State (NYS) to ending the hepatitis C virus (HCV) epidemic was the culmination of years of advocacy on a path that paralleled—and is built upon—the state’s nation leading efforts to end the HIV epidemic. The HCV burden in NYS, and in the U.S.,…